Abingworth
Abingworth invests in life‑science companies developing novel therapeutics, platform technologies and biotech innovations. It targets seed, early‑stage and later‑stage biopharma firms across the US and Europe, providing capital and expertise to accelerate drug development. The firm leverages its transatlantic presence to partner with entrepreneurs building breakthrough medicines.
Based on data we found publicly online. Real numbers may be higher.
What they back
Industries
Companies can be in several industries.
Based on data we found publicly online. Real numbers may be higher.
Based on data we found publicly online. Real numbers may be higher.
How they invest
Deal profile
Check size
Min
$15M
Typical
$22.5M
Max
$30M
Based on data we found publicly online. Real numbers may be higher.
Portfolio composition
Companies by founding year
Peak: 2018: 3 companies
Based on data we found publicly online. Real numbers may be higher.
Fund details
Funds
Based on data we found publicly online. Real numbers may be higher.